Niloufer Khan, M.D.

Dr. Niloufer Khan
Assistant Professor, Department Of Hematology & Hematopoietic Cell Transplantation
Clinical Expertise
Lymphoma
Hematology-Oncology

Hematologist and oncologist Niloufer Khan, M.D., was inspired by her mother, a physician, to pursue a medical career. Dr. Khan understands that a cancer diagnosis is a life-changing and frightening moment for patients, and she is proud to serve as their advocate and guide during treatment. Dr. Khan’s goal as a physician is to deliver high-quality, leading-edge, compassionate and personalized care to her patients, while studying ways to improve their quality of life.

A lymphoma expert, Dr. Khan, came to City of Hope to work with a world-class, multidisciplinary team, including dermatologists and radiation oncologists, to treat patients with lymphoma, particularly T cell, Hodgkin and cutaneous lymphomas. She is a Lymphoma Research Foundation Scholar and, in 2018, she received the American Society of Clinical Oncology’s Young Investigator Award.

Dr. Khan enjoys reading, hiking, cooking and exploring new restaurants in her free time. 
 

Location
Education & Experience
Board Certifications
  • 2021, American Board of Internal Medicine, Medical Oncology 
  • 2020, American Board of Internal Medicine, Hematology 
  • 2016, American Board of Internal Medicine, Internal Medicine 
Degrees
  • 2020, M.S., Clinical Epidemiology and Health Services Research, Weill Cornell Medical College, New York City, New York
  • 2012, M.D., Case Western Reserve University School of Medicine, Cleveland, Ohio
     
Training
  • 2020, Fellowship, Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York
  • 2019, Chief Fellowship, Hematology/Oncology, University of Utah Primary Children’s Medical Center, Salt Lake City, Utah
  • 2016, Chief Residency, Residency and Internship, Internal Medicine, University of Chicago, Chicago, Illinois
     
Professional Experience
  • 2023-present, Assistant Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California
  • 2020-2023, Assistant Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York
Awards & Memberships
Awards
  • 2021, Lymphoma Research Foundation Scientific Research Mentoring Program
  • 2018, American Society of Clinical Oncology Young Investigator Award 
  • 2018-2019, Chief Fellowship, Hematology, Memorial Sloan Kettering Cancer Center 
  • 2017, ASCO/AACR Workshop on Methods in Clinical Cancer Research 2017
  • 2017-2020, Lacher Award for Outstanding Research in Hematologic Malignancies 
  • 2015-2016, Chief Residency, Internal Medicine/Pediatrics, University of Chicago 
  • 2012, Alpha Omega Alpha member
  • 2012, Honors and Distinction in Research, Case Western Reserve University SOM
Memberships
  • American Society of Hematology
  • American Society of Clinical Oncology
  • American Association of Cancer Research
  • American College of Physicians
  • American Academy of Pediatrics
Publications
  • Stuver R, Epstein-Peterson ZD, Johnson WT, Khan N, Lewis N, Moskowitz AJ, Sauter CS, Horwitz S. Current Treatment of Peripheral T-cell Lymphoma. Oncology (Williston Park). 2022 May 9; 36(5): 293-305. PMID: 35576176.
  • Sha F, Okwali M, Alperovich A, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Khan N, Kumar A, Matasar MJ, Moskowitz AJ, Noy A, Owens C, Palomba LM, Rodriguez-Rivera I, Straus D, von Keudell G, Zelenetz AD, Yahalom J, Dogan A, Schöder H, Seshan VE, Salles G, Younes A, Batlevi CL. Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer J. 2022 Feb 10; 12(2). PMID: 35145059
  • Salant JA, Khan N, Nelson JE, Norton-Westbrook M, Desai AV. Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. J Palliat Med. 2021 Jun; 25(6) 958-963. PMID: 34978848.
  • Khan N, Noor S, Horwitz S. How we treat mycosis fungoides and Sezary syndrome. Clin Adv Hematol Oncol. 2021 Sep; 19(9): 573-581. PMID: 34495021.
  • Kumar A, Casulo C, Advani RH, Budde E, Barr PM, Batlevi CL, Caron P, Constine LS, Dandapani SV, Drill E, Drullinsky P, Friedberg JW, Grieve C, Hamilton A, Hamlin PA, Hoppe RT, Horwitz SM, Joseph A, Khan N, Laraque L, Matasar MJ, Moskowitz AJ, Noy A, Palomba ML, Schöder H, Straus DJ, Vemuri S, Yang J, Younes A, Zelenetz AD, Yahalom J, Moskowitz CH. Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. J Clin Oncol. 2021 Apr 28:JCO2100108. doi: 10.1200/JCO.21.00108. Epub ahead of print. PMID: 33909449.
  • Khan N, Lindner S, Gomes ALC, Devlin SM, Shah GL, Sung AD, Sauter CS, Landau HJ, Dahi PB, Perales MA, Chung DJ, Lesokhin AM, Dai A, Clurman A, Slingerland JB, Slingerland AE, Brereton DG, Giardina PA, Maloy M, Armijo GK, Rondon-Clavo C, Fontana E, Bohannon L, Ramalingam S, Bush AT, Lew MV, Messina JA, Littmann E, Taur Y, Jenq RR, Chao NJ, Giralt S, Markey KA, Pamer EG, van den Brink MRM, Peled JU. Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. Blood. 2021 Mar 18;137(11):1527-1537. doi: 10.1182/blood.2020006923. PMID: 33512409; PMCID: PMC7976512
  • Khan N, Feliciano J, Müller K, He M, Tao R, Korol E, Dalal M, Rebeira M, Matasar M. Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. Leuk Lymphoma. 2020 Jul 20:1-8. doi: 0.1080/10428194.2020.1783443. PMID: 32684056.
  • Thom B, Mamoor M, Lavery JA, Baxi SS, Khan N, Rogak LJ, Sidlow R, Korenstein D. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. J Psychosoc Oncol. 2020 Oct 26:1-9. doi: 10.1080/07347332.2020.1836547. Online ahead of print. PMID: 33103948.
  • Mamoor M, Postow MA, Lavery JA, Baxi SS, Khan N, Mao JJ, Rogak LJ, Sidlow R, Thom B, Wolchok JA, Korenstein D. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. J Immunother Cancer. 2020 Mar;8(1):e000260. doi: 10.1136/jitc-2019-000260. PMID: 32152222.
  • Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB, Maloy M, Clurman AG, Stein-Thoeringer CK, Markey KA, Docampo MD, Burgos da Silva M, Khan N, Gessner A, Messina JA, Romero K, Lew MV, Bush A, Bohannon L, Brereton DG, Fontana E, Amoretti LA, Wright RJ, Armijo GK, Shono Y, Sanchez-Escamilla M, Castillo Flores N, Alarcon Tomas A, Lin RJ, Yáñez San Segundo L, Shah GL, Cho C, Scordo M, Politikos I, Hayasaka K, Hasegawa Y, Gyurkocza B, Ponce DM, Barker JN, Perales MA, Giralt SA, Jenq RR, Teshima T, Chao NJ, Holler E, Xavier JB, Pamer EG, van den Brink MRM. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med. 2020 Feb 27;382(9):822-834.
  • Stuver RN, Khan N, Schwartz M, Acosta M, Federico M, Gisselbrecht C, Horwitz SM, Lansigan F, Pinter-Brown LC, Pro B, Shustov AR, Foss FM, Jain S. Single Agents Versus Combination Chemotherapy in Relapsed and Refractory Peripheral T-cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment (COMPLETE) Registry. Am J Hematol. 2019 Jun;94(6):641-649.
  • Khan N, Horwitz S. Immunotherapy in mycosis fungoides: opening night or dress rehearsal? Leuk Lymphoma. 2019 Apr;60(4):864-866.
  • Khan N, Ozkaya N, Moskowitz A, Dogan A, Horwitz S. Peripheral T-cell lymphoma – are we making progress? Best Pract Res Clin Haematol. 2018 Sep;31(3):306-314.
  • Baxi S, Yang A, Gennarelli R, Khan N, Boyce L, Korenstein D. Immune-related Toxicities in PD-1 and PD-L1 Immunotherapies: a Systematic Review and Metaanalysis. BMJ. 2018 Mar 14;360:k793.
  • Khan N, Moskowitz AJ. Where do the new drugs fit in for relapsed/refractory Hodgkin lymphoma? Curr Hematol Malig Rep. 2017 Jun;12(3):227-233.